telisotuzumab adizutecan + fluorouracil + leucovorin + panitumumab

This is an investigational combination regimen of **telisotuzumab adizutecan** (ABBV-400), an antibody-drug conjugate targeting c-Met, combined with **fluorouracil** (5-FU), a pyrimidine antimetabolite, **leucovorin** (folinic acid), and **panitumumab**, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This combination is currently studied for metastatic colorectal cancer (mCRC), aiming to improve response rates by simultaneously targeting c-Met and EGFR pathways along with standard chemotherapy modulation. Telisotuzumab adizutecan delivers a cytotoxic payload to c-Met-expressing tumor cells, while panitumumab blocks EGFR signaling; fluorouracil and leucovorin inhibit thymidylate synthase and enhance chemotherapy efficacy[3][4].

Other names

telisotuzumab adizutecan + 5-fluorouracil + leucovorin + panitumumabtelisotuzumab adizutecan + 5-FU + LV + panitumumab